A 29-year-old woman reaches the registration desk with red welts climbing her neck and a voice that has gone unexpectedly rough. Ten minutes earlier, she had been eating at a wedding; now she says her throat feels “tight,” and she is struggling to finish a sentence. Her blood pressure is falling as the waiting room watches. The next move is still yours.

— What’s your move? Read on.

Before you read
  • Which intervention cannot wait for IV access?
  • What features should determine observation time and disposition?

When to Think of It

Suspect anaphylaxis with sudden skin or mucosal involvement plus respiratory compromise or hypotension; involvement of two or more systems after a likely allergen; or hypotension after exposure to a known allergen. Skin findings may be absent. Hoarseness, stridor, wheeze, hypoxemia, syncope, and poor perfusion are danger signs.

Sick or Not Sick

The key call is whether there is airway, breathing, or circulatory compromise. If yes—or if symptoms are rapidly progressing—treat immediately; do not wait for a rash, laboratory testing, or IV access.

The First Fifteen Minutes

  • Suspected anaphylaxis: Epinephrine 0.3–0.5 mg IM (1 mg/mL solution) into the mid-anterolateral thigh; repeat every 5–15 minutes if airway, breathing, or circulatory symptoms persist. It reverses vasodilation, edema, and bronchospasm.
  • Hypotension or poor perfusion: Give 1–2 L isotonic crystalloid IV rapidly, reassessing and repeating as needed; capillary leak and vasodilation create profound intravascular depletion.
  • Persistent bronchospasm after epinephrine: Give albuterol 2.5–5 mg nebulized, repeat every 20 minutes as needed; it adds bronchodilation but does not replace epinephrine.
  • Refractory shock despite repeat IM epinephrine and fluids: Start epinephrine 1–10 mcg/min IV infusion, titrated in a monitored setting. Infusion preparation and dosing vary by protocol; check the institutional reference.
  • Beta-blocker use with refractory shock: Consider glucagon 1–5 mg IV over 5 minutes; if response, an infusion of 5–15 mcg/min IV may be used. Dosing varies; check a reference and anticipate vomiting.
  • Antihistamines are only for persistent skin symptoms after stabilization: cetirizine 10 mg PO, or diphenhydramine 25–50 mg PO/IV. For persistent urticaria, famotidine 20 mg PO/IV is an optional adjunct. None treats airway edema or shock.
  • Reassess voice, work of breathing, perfusion, and response after each intervention; summon airway expertise early if edema is progressing.

Definitive Care & Disposition

Remove the trigger if possible and involve airway/anesthesia support early for progressive upper-airway symptoms. Observe according to severity and response: longer observation or admission is appropriate after severe hypotension, airway involvement, repeated epinephrine, delayed response, or ongoing symptoms. Discharge only when stable, with an epinephrine autoinjector 0.3 mg IM device prescription (typically provide two), hands-on teaching, a written action plan, and allergy follow-up. Observation recommendations vary; use local guidance and individualize for biphasic-reaction risk. Corticosteroids have not been shown to reliably prevent biphasic reactions.

How This One Kills

Waiting for IV access—or giving antihistamines first—while laryngeal edema or shock progresses. The patient may lose the airway before the team recognizes that the first-line intervention was delayed.
The Differential — What Else Looks Like This
  • Isolated urticaria — No respiratory, cardiovascular, or significant gastrointestinal involvement; confusing it with anaphylaxis can lead to overtreatment, while missing progression can be dangerous.
  • Bradykinin-mediated angioedema — Often lacks urticaria and itching, and may occur with ACE-inhibitor use; assuming a histamine mechanism can delay airway planning and disease-specific treatment.
  • Vasovagal syncope — Bradycardia, pallor, and rapid improvement supine favor it over anaphylactic shock; confusing the two can delay epinephrine.
  • Acute asthma — Wheeze without a trigger-associated multisystem reaction favors asthma; treating wheeze alone misses evolving anaphylaxis.

The Second-Day Story

Older adults may present with syncope, weakness, or hypotension and have little or no rash; beta-blockers can blunt tachycardia, and early symptoms may be mistaken for a medication reaction or cardiac event. Look for abrupt onset after a plausible exposure, new hoarseness or wheeze, mucosal swelling, and a change from baseline perfusion. A normal skin exam does not rule it out.
Back to Our Patient
Back to our 29-year-old with the rough voice and rising welts: the sudden skin and mucosal findings with progressive throat symptoms and falling blood pressure meet the bedside threshold for anaphylaxis. The management fork is clear—she has airway and circulatory compromise—so give IM epinephrine immediately, repeat it if needed, and rapidly infuse crystalloid for persistent poor perfusion; prepare for early airway intervention if her voice or breathing worsens. Once stabilized, she needs monitored observation and admission if symptoms recur, repeated epinephrine is required, or airway concerns persist; discharge is appropriate only after sustained stability with autoinjectors, teaching, and follow-up.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 29-year-old woman with rapidly progressive rash, throat tightness, and hypotension after eating at a wedding. Ten minutes after eating, she developed pruritic welts and a hoarse voice, then became lightheaded; she has no known prior reaction or new medication exposure. She is tachycardic and hypotensive, with diffuse urticaria and hoarseness but no stridor or visible tongue swelling. Her oxygen saturation is 95% on room air, and her lungs have no wheeze. This is anaphylaxis with evolving upper-airway symptoms and circulatory compromise. I’m giving IM epinephrine now, starting rapid IV crystalloid, and reassessing airway and perfusion while preparing for early airway support. She will need monitored observation and admission if symptoms persist or recur.”

Study Directive

  • From memory, state the three clinical routes to diagnosing anaphylaxis and identify which one does not require skin findings.
  • Practice drawing the correct IM injection site and stating the adult dose, concentration, and repeat interval without prompting.
  • Run a two-minute scenario with a partner: one patient becomes hypotensive despite the first IM dose; verbalize reassessment, fluid resuscitation, repeat epinephrine, and escalation to an infusion.
  • Compare your institution’s observation and discharge guidance with a recognized emergency reference; write down the local criteria for extended observation and admission.

Recent Literature

  • Review or guideline Anaphylaxis: A 2023 practice parameter update
    Golden DBK, Wang J, Waserman S, et al. · Ann Allergy Asthma Immunol, 2024 · PMID 38108678 · cited 347×
    Give intramuscular epinephrine promptly, then tailor observation and discharge planning to the patient’s risk of recurrent symptoms.